Nokia Corporation: Repurchase of own shares on 31.01.2023
Stock Exchange Release
31 January 2023 at 21:00 EET
Nokia Corporation: Repurchase of own shares on 31.01.2023
Espoo, Finland – On 31 January 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:
|Trading venue (MIC Code)||Number of shares||Weighted average price / share, EUR*|
* Rounded to two decimals
On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and ends at the latest by 21 December 2023 with a maximum aggregate purchase price of EUR 300 million.
Total cost of transactions executed on 31 January 2023 was EUR 1,377,639.60. After the disclosed transactions, Nokia Corporation holds 39,651,478 treasury shares.
Details of transactions are included as an appendix to this announcement.
On behalf of Nokia Corporation
BNP Paribas Exane
At Nokia, we create technology that helps the world act together.
As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks. We create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs.
Adhering to high standards of integrity and security, we help build the capabilities needed for a more productive, sustainable and inclusive world.
Phone: +358 40 803 4080
David Mulholland, Head of Investor Relations
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Anaqua Provides Platform for Intellectual Property Management to Fujitsu28.3.2023 14:00:00 CEST | Press release
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Anaqua, the leading innovation and intellectual property (IP) management technology provider, today announced that information and communications technology company Fujitsu has adopted Anaqua’s AQX platform to optimize the digital management of the company’s IP portfolios. Anaqua will provide its AQX platform to Fujitsu to seamlessly connect and enhance global collaboration among R&D sites, IP departments, and outside counsel, bringing increased efficiency to the development of IP and management of the innovation lifecycle. AQX will also help empower Fujitsu in the timely execution of their global IP strategy through the establishment of a more data-driven approach to developing and maintaining an IP portfolio that best supports the broader business. In addition, through Anaqua’s cloud hosting services and commitment to security, certification processes, and compliance programming, the AQX platform will deliver a robust security environment fo
Resolutions by the Annual General Meeting of Municipality Finance Plc held on 28 March 202328.3.2023 14:00:00 CEST | Press release
Municipality Finance Plc Stock exchange release 28 March 2023 at 3.00 p.m. (EEST) Resolutions by the Annual General Meeting of Municipality Finance Plc held on 28 March 2023 The Annual General Meeting (hereinafter the AGM) of Municipality Finance Plc (MuniFin) held on 28 March 2023 adopted the company’s financial statements and discharged the members of the Board of Directors (the Board), the CEO, and the Deputy to the CEO from liability for the financial year 2022. Use of Profit Shown on the Balance Sheet and the Distribution of Dividend The Annual General Meeting decided that a dividend of EUR 1.73 per share, totalling 67,580,370.54 EUR shall be paid out. Dividends will be paid on 13 April 2023 to each shareholder recorded in the company's list of shareholders on 4 April 2023. Remuneration and Composition of the Board The AGM decided on the remuneration for the members of the Board for the term from the closing of the 2023 AGM, to the closing of the next AGM (the Term 2023–2024) as f
Decisions taken by Enento Group Plc’s Annual General Meeting and Board of Directors28.3.2023 14:00:00 CEST | Press release
ENENTO GROUP PLC, STOCK EXCHANGE RELEASE 28 MARCH 2023, 3:00 P.M. EEST Decisions taken by Enento Group Plc’s Annual General Meeting and Board of Directors The Annual General Meeting of Enento Group Plc was held today at the headquarters of the company in Helsinki. 100 shareholders representing 20 007 462 shares and votes were represented at the meeting. The Annual General Meeting approved the Financial Statements and discharged the members of the Board of Directors and the company's CEO from liability for the financial year 2022 and resolved to approve the Remuneration report for governing bodies. The Annual General Meeting approved the Board of Directors' proposal to distribute funds of EUR 1.00 per share as an equity repayment from the reserve for invested unrestricted shareholders’ equity of the company. The equity repayment will be paid to shareholders who are recorded in the company's shareholder register maintained by Euroclear Finland Ltd on the record date of the payment on 30
HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression28.3.2023 14:00:00 CEST | Press release
KET01 Phase 2 Clinical Trial with Topline Results Expected Mid-Year MUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, together with Develco Pharma, announced today that the last patient has been randomized in its proof-of-concept Phase II clinical trial of ‘Ketabon’ (KET01), an oral prolonged-release ketamine formulation (KET01) for Treatment-Resistant Depression (TRD). Topline data from the Phase 2 trial, which is investigating efficacy, safety, and tolerability, is expected to be reported soon after the last study visit. Enrollment in the Phase 2 trial commenced in June 2022 and 122 patients with treatment-resistant depression (TRD) have now been randomized at 29 clinical sites. Patients were selected based on current major depressive episodes not responding to a minimum of two standard antidepressants. The trial design
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients28.3.2023 13:46:26 CEST | Press release
New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data on time (Q4 2023)Increased focus extends cash runway significantly COPENHAGEN, Denmark, March 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, today announces an increased focus on its strategy around its core AI capabilities allowing fast and de-risked development of its pipeline. Recently, Evaxion announced that the Company has used its proprietary AI technology to discover a new treatment opportunity that may broaden cancer immunotherapy. Through new cancer targets, so-called ERVs (endogenous retroviruses), it may become possible to treat cancer patients who have until now been considered unresponsive to immunotherapy. This opens